Get started

Biotech

HALBERD CORPORATION· Current Price – $0.0419 · Best Case Scenario PT over 1$ · Market Cap – $11 million · Debt – 0 Halbert Corporation Are a biomedical company with a clear aim to revolutionize the world of medicine. They are working towards a creation of variety of antibodies and treatments using extracorporeal techniques (outside of body). They believe they have the technology to cure diseases like, Covid-19, PTSD, Cancer, CTE, tuberculosis, malaria, strokes and heart attacks, blood sepsis, Alzheimer’s Disease. In the last 8 months they have secured 7 provisional patents (which give the global rights) to technology of treating severe Covid-19 patients, Covid-19 nasal spray, antibody cocktail to boost immune system against Covid - 19 and recently developed two new antibodies that no other big pharma has, which allows them detect Covid-19 in matter of minutes using saliva or blood samples. Furthermore, are working with $GRPS to develop anti-addiction patches (alcohol, drugs, nicotine). To achieve their further goals they have carefully selected to partner with Arizona State University (who have won the first place in innovation for the last 6 years going in the USA, higher than MIT or Stanford). This partnership has already delivered amazing milestones and they are already working towards filing for new joint provisional patents. Halbert has 0 debt, yes ZERO and been receiving funding in 2 million chunk donations due to promising results. Halberd’s corporate charter also prohibits them from issuing any kind of convertible financial instrument, debt or preferred stock, however the corporation shall be able to issue warrants or options. Management team has extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment. Furthermore, the ultimate catalyst, which seems quite likely is for Halbert to partner or licence their technology to one of the big pharma as the CEO, William has mentioned so on multiple occasions. In the past, he has been approached by the big pharma (Pfizer and Novartis), and hopes the same will happen with their revolutionary technology. Issued Patents 2014 - Sequential Extracorporeal Treatment of Bodily Fluids 2015 - Utilization of Stents for the Treatment of Blood Borne Carcinomas Provisional Patents 11/2020 - Fluorescent Antibody’s in Covid-19 Detection & Treatment 10/2020 - Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (Covid-19 Virus). 10/2020 - Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus 09/2020 - Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans 04/2020 - Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus 04/2020 - Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients 03/2020 - Method for Treating and Curing Covid-19 Infection Future Patents During podcasts and interviews the CEO said he will announce another 2 patents soon. They are waiting to achieve provisional status to ensure the technology is safe. Further patents are in the pipeline as CEO’s devised a strategy to secure as many patents as they can, of which they could then either licence or partner on developing on joint ventures with big pharma. Upcoming Catalyst 2021 · 2 patent provisional applications yet to be announced · Development of antibody cocktail vitamins to boost immune system against Covid-19 (Q2 launch and start to generate revenue) · Development of Covid-19 Nasal Spray · Commercial development of Covid-19 test using saliva or blood (takes only a minute no nasal swap which is uncomfortable) · Patent Licencing to other pharma companies – they produced antibodies that are stronger than some of the big pharma · Partnerships and joint ventures with other organizations · Discovery of new treatments and patent fillings · Further development of extracorporeal technology to treat cancer, PTSD, Alzheimer’s, blood sepsis, CTE · Anti-addiction patches Sociability Factor In penny stock market, especially during current times (rise of social media and social traders) the CEO’s or the organization being sociable, sharing achievements, milestones, ethos and so on can have a massive impact on the share value. In this regard, Halberd’s corporation in my view would score high points. They tend to release anywhere between 2/5 press releases a month in which various milestones would be announced via text, video interviews or podcasts. Senior Leadership Team The CEO’s aim was to ensure that they develop a very cohesive team of talented people to achieve greatness. Here below I have listed a few KEY members including bio snapshots. Business Advisory Board The CEO – based on the videos and podcasts that are available (6+) of William A. Hartman sounds very ambitious and driven on a mission to be the best in the industry and revolutionize medicine. He believes Halberd corporation share value should be worth $1 per share. This may sound like very ambitious venture for some, however, let us not forget he founded and headed separate business group within TRW Automotive with plants in the U.S., Mexico and Europe that produced combined annual sales of $1.3 Billion – this shows extreme capability. He has also worked as COO for Nanologix, Inc, President and CEO of Premier Biomedical. I would recommend checking out any of his interviews to feel his passion. Carl Eller - retired NFL Pro Football Hall of Famer, and President of the NFL Retired Players Association, was drafted in 1964 as the league’s 6th pick overall by the Minnesota Vikings, he became a major factor as a defensive end with the unit known as the “Purple People Eaters.” Eller became a six-time Pro Bowl player who appeared in four Superbowls and is currently focused on helping former players transition into retirement. Alec Torelli - is an entrepreneur, author, motivational speaker and professional poker player who has worked with various companies to apply his life experiences/lessons from poker, in a practical manner, to carry out their corporate visions, increase sales and/or improve service delivery while creating meaningful lives for their employees. Scientific Advisory Board Mitchell S. Felder, MD - is a prolific inventor. He is a Board Certified Neurologist and former CEO, President, Chairman and founder of Infectech and Nanologix, and currently serves as Locum Tenens Attending Neurologist with UPMC Pennsylvania Dr. Felder has authored or co-authored six publications, three studies and has currently 21 issued patents. Dr. Felder was the Acting Chief of the Department of Neurology, Sharon Regional Health System from 1989 until 2001. Dr. Felder served as the Acting Chief of the Department of Neurology at the William Beaumont Army Medical Center in 2011. Dr. Qiang (Shawn) Chen, who is the Principal Investigator at ASU, in charge of the research and development for Halberd Corp: Take a look at his research projects over the last 4-5 years and you see why this HALB/ASU cooperation is a marriage made in heaven. Only weeks ago, Halberd signed another R&D-agreement with GreenBioAZ inc, it's a start up from Arizona State University and will do research for Halberd's radiofrequency technology. Dr. Chen is CEO of GreenBioAZ Patricio Reyes, MD, FAAN - a board certified neurologist and neuropathologist, and Chief of Neurology/TBI/Alzheimer’s Disease/Cognitive Disorders at the VA Medical Center in Phoenix, Arizona and is a Board Member of the Retired National Football League Players Association. Dr. Reyes is a board member, and former Chair of the Education Committee and 2009 Distinguished Educator of the Association of Ringside Physicians. HALB has access to the VA Hospital Group because of Dr. Reyes. Timeline of Key Press Releases I have gone through the list of all of their press releases (they post regularly) and compiled key updates here below: April 6, 2020 - Halberd announces agreement to retire 192,000,000 outstanding common shares and reduced authorized shares of common stock to 1,000,000,000. April 8, 2020 – Halberd, Premier Biomedical ($BIEI) and Gold River Productions ($GRPS) announce the signing of a multi-faceted agreement for ongoing R&D into a potential treatment and cure for Covid-19 as well as development of Premier’s Anti-Addiction Patch. July 1, 2020 - Halberd establishes United Kingdom subsidiary to facilitate access to European research facilities and markets to establish a global footprint. July 13, 2020 - Halberd’s corporate charter prohibits it from issuing any kind of convertible financial instrument, debt, or preferred stock. August 4, 2020 - Halberd secures $2 Million for Covid-19 Research August 31, 2020 - Halberd signed an agreement with Arizona State University (ASU) to conduct sponsored research to develop Halberd’s Covid-19 treatments. September 21, 2020 - Covid-19 Research Program Progress – Successful Covid Spike Protein Disease Antigen September 24, 2020 - Successful creation of a fluorescent antibody, that will help them create a rapid Covid-19 test using saliva or a drop of blood. This approach will allow for accurate test results in a matter of minutes – believe travel industry may benefit from this approach. October 8th, 2020 – CEO’s letter of updates and accomplishments October 13, 2020 – Halberd and ASU Develop Antibody Against Covid-19, pursuing new joint patent. October 19, 2020 – in process to filing a new joint patent with AUS for creation of a new class of anti-Spike protein monoclonal antibodies against Covid-19. This protein will allow extremely rapid identification of the Covid-19 virus in nasal mucus, saliva, and blood. October 29, 2020 – Strategic plan curing blood sepsis, Alzheimer’s Disease, Heart Attack and Stroke using extracorporeal process November 12, 2020 – Patent pending for Covid-19 detection test from saliva or blood in minutes. December 1, 2020 – Halberd re-organizes advisory board. December 17, 2020 - Halberd Corporation Pursues Extracorporeal Radio Frequency Treatment Against Covid-19 December 23, 2020 - Halberd Produces a Second Monoclonal Antibody Against Covid-19 Spike Protein – “Mathematically speaking, if each is 90% effective independently, then, absent any interrelationship of the two applications, the combination should be 99% effective. In other words, the prospect of obtaining diagnostic test false positives or false negatives is substantially reduced when antibodies work in tandem” January 4, 2021 - Halberd Corporation 2020 Year End CEO Letter, looking forward to 2021 January 14, 2021 - Halberd Develops Medication to Boost Immune System Against Covid-19 February 16, 2021 - Halberd has engaged GreenBioAZ to conduct laboratory testing of Halberd’s patent pending Radio Frequency (RF) extracorporeal treatment to eliminate infectious disease. March 2, 2021 - Halberd’s 2nd Proprietary Antibody Against SARS-COV-2 Spike Protein Demonstrates Neutralizing Affinity 20 Times Greater - “We are excited about the progress being made in developing Halberd’s effective proprietary antibodies against Covid-19. These results put our antibody in the same realm of effectiveness as the best-known competitive SARS-COV-2 antibodies. Since posting links may take an excessive amount of space here, you can find all the press releases here and search by date, plenty more to see that are not included in my post - Hope people found this helpful and I look forward to seeing what the future holds for $HALB!
OTC:HALBLong
by headdeveloper33
1
BIOL Back In The Channel AgainIt's almost exhausting watching BIOL do this every time...jump, fall, jump, fall, all right back to this channel. There's an interim gap to fill from a few weeks back but still many other levels to consider IF it can break back above and out of this channel. I think volume will be an indicator to watch in consideration of whether or not this can happen. Because dental procedures have resumed to most of their pre-covid levels, many investors are bullish on the future of Biolase. While it is affected by the pandemic, the company is working to build new strategies. This goes hand in hand with its need to continue innovating and receiving new patents. With all of this in mind, is BIOL a penny stock to watch? Quote Source: 5 Biotech Penny Stocks On Robinhood To Watch In March 2021
B
by PennyStocks101
3
SYN Still Trying To Fill The GapThere's still a pretty big gap to fill from a few years ago but again, with a lot of biotech gaining recently, small caps could be back on the menu. After Maxim Group upgraded SYN from a hold to a buy, shares of the biotech company dramatically increased. In addition to this, Maxim Group analysts gave a price target for SYN of $2.50. This represents a 10% or so gain from where it was before the rating. At the end of Friday, March 12th, SYN stock had shot up by over 29% to $0.92...CEO Steven Shallcross stated that “we are more encouraged than ever by this outlook for the business as we have made important progress during the fourth quarter advancing and demonstrating the significant value of our clinical development programs. With a number of upcoming catalysts later this year, we believe there is potential to continue to deliver significant value for our shareholders.” Quote Source: 5 Biotech Penny Stocks On Robinhood To Watch In March 2021
S
by PennyStocks101
1
Back At Historical S/R Level On ISRISR has been something of a sight in this market. Now, after pulling in and settling down a bit, it's back at the historic support/resistance level. With momentum acting as a tailwind in biotech stocks, overall, I'll be interested to see if it can get back above this level in more of a "calm fashion" haha. While fewer surgeries occurred last year due to covid, IsoRay has managed to work around this, building its brachytherapy use cases along the way. CEO Lori Woods stated that “we are very pleased that we have been able to continue to make progress this quarter despite the ongoing challenges that the Covid-19 pandemic has presented. Amongst the highlights has been our continued success in expanding adoption of Celsium-131 in our core prostate market.” Quote Source: 5 Biotech Penny Stocks On Robinhood To Watch In March 2021
I
by PennyStocks101
$INVO Expands Amended U.S. Commercialization AgreementINVO Bioscience Expands Company-Owned Clinic Opportunity Under Amended U.S. Commercialization Agreement $INVO today announced an amendment under its exclusive U.S. commercialization agreement with Ferring Pharmaceuticals. The amendment provides for an increase in the number of INVO company-owned clinics initially allowable under the agreement and removes certain geographical restrictions. The amendment also adjusted the remaining annual 2020 minimum contractual product purchase requirement, whereby Ferring will place a $501,000 order, which will be recognized as revenue by INVO Bioscience in the first quarter of 2021.
I
by AlenCiken
BTIG buy recommendation with $14.00 price target- 360.5% upsideShares of $SEEL skyrocketed today after BTIG initiated coverage on the stock with a buy recommendation and a one-year price target nearly 4.7 times higher than Seelos' closing price on Thursday. BTIG analyst Robert Hazlett likes the prospects for Seelos' pipeline. Last week, the biotech announced that it had completed enrollment in a pivotal proof-of-concept study evaluating SLS-002 in treating acute suicidal ideation and behavior in patients with major depressive disorder. Seelos also has two other clinical-stage candidates. It's evaluating SLS-005 in phase 2 studies for three neurodegenerative disorders: amyotrophic lateral sclerosis (ALS), rare genetic disease Sanfilippo syndrome, and oculopharyngeal muscular dystrophy. Seelos should report key data from its study of SLS-002 in the second quarter of this year. Seelos also plans to advance SLS-005 into a pivotal phase 2b/3 clinical study targeting ALS in the first half of the year. www.fool.com seekingalpha.com
S
by AlenCiken
$ENTX Entera Bio Ltd Announces Positive Topline EB613 Phase 2Entera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data ‒ Trial Met Primary Endpoint of Significant Increase in P1NP Based on Final Analysis of 3 Month Data ‒ Final Analysis of 6-Month Data, Including Change in Bone Mineral Density, Expected in Q2:21 ‒ The trial’s primary endpoint was met - the complete 3-month results from the trial showed a significant increase in the P1NP biomarker in the 2.5 mg dose group after 3 months of treatment (P <0.04) as compared to placebo. ‒ Similar to the increase in P1NP, a significant increase in Osteocalcin was also observed in the 2.5 mg group after 3 months (P <0.01). ‒ In line with a potential anabolic effect, a significant decrease in CTX was observed after 3 months of treatment (P <0.015). The decrease in CTX taken together with the increase in P1NP and Osteocalcin would indicate a potential positive impact on BMDand a reduced risk of fractures, which is the goal of an anabolic osteoporosis treatment. ‒ Entera intends to submit the full dataset for publication and/or presentation at an upcoming medical conference.
NASDAQ:ENTX
by AlenCiken
NLS Obtains License to Full Regulatory Data Package and know-howNLS Pharmaceutics Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex® (Mazindol) Agreement provides exclusive rights to all available data included in the original new drug application ("NDA") for mazindol in the U.S. $NLSP announces that it has entered into a License Agreement (the "Agreement") with Novartis Pharma AG, whereby the Company has obtained, on an exclusive basis in the United States, all of the available data referred to and included in the original NDA for Sanorex® (mazindol) submitted to the United States Food and Drug Administration in February 1972. The Agreement encompasses all preclinical and clinical studies, data used for manufacturing including stability and other chemistry manufacturing and controls data, formulation data and know-how for all products containing mazindol as an active substance, and all post-marketing clinical studies and periodic safety reports from 1973 forward. Under the Agreement, NLS has obtained the same rights on an non-exclusive basis in all territories outside of the U.S, except for Japan, with the right to cross-reference the Sanorex NDA with non-U.S. regulatory agencies in the licensed territories. finance.yahoo.com
NASDAQ:NLSP
by AlenCiken
Why $EYES Skyrocketed 1233% in March?$EYES Receives FDA Approval for the Argus 2s Retinal Prosthesis System $EYES today announced U.S. FDA has approved the Argus 2s Retinal Prosthesis System, a redesigned set of external hardware (glasses and video processing unit) initially for use in combination with previously implanted Argus II systems for the treatment of retinitis pigmentosa (RP). The Company expects that the Argus 2s will be adapted to be the external system for the next generation Orion Visual Cortical Prosthesis System currently under development. In addition to ergonomic improvements, the Argus 2s system offers significantly more processing power, potentially allowing for improved video processing. A decision on when or if to begin production of the newly approved hardware is pending completion of Second Sight’s planned business combination with Pixium Vision, which currently is in progress. Should the business combination be completed, the new management team will then evaluate how best to proceed with the Argus 2s Retinal Prosthesis System, as well as all other products in development. finance.yahoo.com
E
by AlenCiken
BIT BreakoutASX:BIT Biotron Limited is engaged in the research, development, and commercialization of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1, and a promising preclinical program for HBV. In addition, Biotron has several earlier stage programs designing drugs that target a class of virus protein known as viroporins which have a key role in the virus life cycle of a very broad range of viruses, many of which have caused worldwide health issues such as Dengue, Ebola, Middle East Respiratory virus, Influenza and Zika viruses. Bullish Outlook: - If Daily Resistance fails I have a Golden Pocket Target after Identifying previous Breakout Cycles - Bullish Breakout from long-term downtrend - FIB Retracement Golden Pocket 0.5-0.618 has been previously respected - RSI Passed the 50.00 level and is now Bullish - MACD Bullish Cross "DISCLAIMER: NO ADVICE. The information presented here is general in nature and is for education purposes only. Nothing should be considered to be advice. You should consult with an appropriate professional for specific advice tailored to your situation."
ASX:BITLong
by Trader_Johnni
EVGN: Leading Expanding Diagonal? Looks attractive to me!A buddy of mine mentioned this when we spoke about "high conviction trades" My HCT is 3D printing. This is his. I took a look and it appears we're setting up for what appears to be a potential 5th wave of a leading diagonal. This in theory if it proves to be right, should kick off the first motive cycle. Right now it looks like it can go either way. If price breaks out bullish thru the current structure I think we will be in for a treat. All in all, seems like a solid play. I'll be looking for buy setups from now till exhaustion is seen on the 5th wave of the cycle. What are your views on EVGN? Solid biotech pick, or a meme stonk? Thanks for looking, and I'm looking forward to others opinions! Trade safely!
NASDAQ:EVGNLong
by adambiers
2
CRSP short trade updates on weekly chartHere is my follow up update on original CRSP swing short trade idea I put up on January 14th. On this post, I am zooming out to weekly chart, looking at longer time frame to capture cyclical trends. Going back all the way to 2017 inception period, the higher than average volatilities are pretty easy to notice. It moves up really fast but also coming down. Every single time it has entered bear market or the sell signal is triggered, it has corrected well into double digit, easily averaging over 50%. In addition, RSI being overbought and high level PPO bearish cross overs are clear indication to trend reversal as well. Lastly, the week is too young still to comment yet but as of the end of today's session, it has taken down the up trend line as well on the weekly chart. There are plenty of time left in the week to recover the trend line but we shall see. It would be bullish if it can snap back above by the end of this week. I do not think CRSP will drop to my potential max targets without decent double digit correction in SPY and QQQ. I will comment on this post after the Friday close to see where it will be by then. If anyone has any thoughts either bullish or bearish, I would love to hear from you. Also, if you find it interesting, please follow me here. Have a good trade everyone, T.
NASDAQ:CRSPShort
by TK0421
2
Takeda Secures Global Rights from Ovid TherapeuticsTakeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome. Ovid eligible to receive up to $856M in payments, including a $196M upfront payment, regulatory and commercial milestone payments and tiered double-digit royalties on product sales − Original 2017 collaboration between Ovid and Takeda to conclude; Ovid will have no further development or milestone obligations. In addition, Ovid will receive tiered royalties beginning in the low double-digits and up to 20 percent on sales of soticlestat, if approved and commercialized. Takeda intends to initiate Phase 3 studies of soticlestat in children and young adults with DS and LGS in calendar year Q2 2021. finance.yahoo.com
NASDAQ:OVID
by AlenCiken
$KMPH Announces FDA Approval of AZSTARYS™KemPharm Announces FDA Approval of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD Corium, Inc. will lead the commercialization of AZSTARYS per the definitive collaboration and license agreement. Corium expects to make AZSTARYS commercially available in the U.S. as early as the second half of 2021. Under the License Agreement, KemPharm may be eligible for up to $468 million in regulatory and sales milestone payments, as well as tiered royalty payments, on a product-by-product basis for net sales, with potential percentages up to the mid-twenties for U.S. net sales, and up to the mid-single digits of net sales in each country outside of the U.S. finance.yahoo.com
K
by AlenCiken
1
Strong pan-coronavirus effectiveness of clinical drug candidatesPan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application $NNVC reported yesterday on the strong pan-coronavirus effectiveness of its two COVID-19 clinical drug candidates for which the Company is preparing a pre-IND application. NV-CoV-2 is the Company's broad-spectrum anti-coronavirus clinical lead drug candidate for the treatment of COVID-19 patients based on its nanoviricides® platform. $NNVC is also developing NV-CoV-2-R, a drug treatment that combines the power of both NV-CoV-2 and remdesivir in a single drug that encapsulates and protects remdesivir inside NV-CoV-2. Both NV-CoV-2 and NV-CoV-2-R are expected to work against most, if not all , coronaviruses and their variants, based on the Company's findings on their pre-clinical effectiveness discussed below. NV-CoV-2 and NV-CoV-2-R were found to be highly effective in comparison to remdesivir against two distinctly different coronaviruses in our new cell culture studies leading towards a pre-IND application and thereafter an IND submission for these COVID-19 drug candidates. The Company intends to report on the results of these studies in its pre-IND application to the US FDA to obtain guidance regarding human clinical trials for treatment of COVID-19 patients. Additionally, the Company is actively seeking opportunities to engage appropriate sites for human clinical trials. Further, the Company is engaged in the preparation of clinical trial protocols and other activities that would be necessary for submitting an IND application to the US FDA. The Company has developed NV-CoV-2 based on its platform nanoviricides® technology. This approach enables rapid development of new drugs against a number of different viruses. finance.yahoo.com
AMEX:NNVC
by AlenCiken
2
SONA NANOTECHDowntrend broken. Bullish flag on the 1 hour while trading tight with the 9 EMA. Above average volume past 2 days with no news? Leak ? This play is known for it's volatility and leaky news, market is expecting good update about the company's new Covid-19 saliva test, along with sales, revenue projections, and regulatory approvals. Either one of those will increase the sp drastically. If all goes well, I really see this play breaking it's previous ATH of $16, but for now remain cautiously optimistic. Short term goal is $8, can change depending on what the company releases. Drop your targets below or what news you think we will hear next. Long on SONA.CN
CSE:SONALong
by SamView2920
After six-week slide, I am buying MerckMerck is one of my favorite pharmaceutical companies. As far as I can tell, it a genuinely ethical and well-managed company with an above-average ESG rating. Merck has executed pretty consistently, with an average of 2% annual sales growth, 2.5% annual dividend growth, 3% annual earnings growth, and 4% annual free cash flow growth over the past several years. Merck's valuation is quite attractive for a growing, large-cap company. I estimate its forward P/E at 10, forward P/S at 3.4, and PEG under 5. Merck's dividend yield is a juicy 3.76%, and they should have no problem sustaining that given their free cash flow growth. I estimate that Merck has about 16% upside to its median price multiple of the last four years. Market sentiment is quite bullish on Merck. The average analyst summary score is a "buy" at 6.4/10. Merck has about 30% upside to its average analyst price target. Open interest from option traders is in highly bullish territory, with a put-call ratio of 0.56. News lately has been a bit negative for Merck. Today they voluntarily withdrew their drug Keytruda for one of its (many) indications because it didn't meet FDA post-marketing requirements. That's not great, but it won't be devastating to Keytruda revenues. Merck's proposed purchase of Pandion Therapeutics is being investigated for procedural problems, which also isn't great. Plus, the FDA delayed approval of Merck's application for emergency approval for its Covid-19 drug until it produces more data. On the other hand, Merck just submitted a New Drug Application for gefapixant and cut a billion-dollar commercialization deal for Xevinapant. Both those things are positives for the company. Plus, Merck got some positive attention recently due to a large purchase of its stock by Warren Buffett's investment fund. In technical terms, Merck obviously has been in a downtrend, but it's approaching trend line support. I'm looking at buy tomorrow in the $71.50-71.75 range if Merck continues to dip toward support.
NYSE:MRKLong
by ChristopherCarrollSmith
3
Tight Risk Reward, Good CompanyMersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. After an insider at Mersana Therapeutics bought shares following a May 2020 selloff triggered by an interim data release, the stock rallied over 400% during the next eight months. Another bounce back may emerge again with an insider purchasing shares after a one-day plunge of nearly 30% on tepid but still encouraging data from its lead ADC asset. A 180-patient single-arm registrational trial is set to be initiated for XMT-1536 in the treatment of platinum-resistant ovarian cancer this quarter. With early-stage clinical data due from both its candidates in the treatment of NSCLC adenocarcinoma in 2H21, Mersana merited another look. I like it long here as tight risk-reward play.
NASDAQ:MRSNLong
by pivotanalytics
2